投資企業(yè)新聞
啟明星 | 江蘇正大豐海制藥與 Insilico Medicine 合作新藥開發(fā) | Bilingual
2019/10/09
|
啟明創(chuàng)投
江蘇正大豐海制藥有限公司（CTFH）與啟明創(chuàng)投投資企業(yè)、人工智能藥物開發(fā)的領(lǐng)導(dǎo)者 Insilico Medicine，簽訂了2個(gè)項(xiàng)目的AI技術(shù)開發(fā)服務(wù)合同，包含復(fù)雜高難度而且傳統(tǒng)上無法設(shè)計(jì)藥物的靶點(diǎn)，特別是對三陰性乳癌患者的治療，藥物開發(fā)結(jié)合了創(chuàng)新的AI技術(shù), 可望加速開發(fā)成果的實(shí)現(xiàn)，對于患者而言將是一大希望。此合作計(jì)劃案包括首付款，里程碑款項(xiàng)和銷售上市績效獎(jiǎng)勵(lì)，合作成功后項(xiàng)目總價(jià)值預(yù)計(jì)可達(dá)2億美元。
江蘇正大豐海制藥全心致力于科技創(chuàng)新和新藥開發(fā)，在一類新藥研發(fā)方面已有里程碑式的成果。總經(jīng)理夏文余表示，很高興與 Insilico Medicine 建立合作伙伴關(guān)系，相信通過與 Insilico Medicine 的合作將大幅加速藥物開發(fā)的速度及提升效率，并將引導(dǎo)企業(yè)應(yīng)用嶄新的藥物開發(fā)方法。Insilico Medicine 利用AI生成具有特定性質(zhì)的全新分子, 將之用于藥物發(fā)現(xiàn)領(lǐng)域?qū)偃蛞涣?，通過其AI平臺(tái)的優(yōu)勢，可以加速藥物開發(fā)進(jìn)程，更能降低開發(fā)成本，相信此合作模式將可迅速地為社會(huì)大眾提供更具有經(jīng)濟(jì)效益的產(chǎn)品，以造就人類福祉。
今年9月，Insilico Medicine 在 Nature Biotechnology 期刊發(fā)表具有里程碑意義的論文，利用生成性張力強(qiáng)化學(xué)習(xí)（GENTRL）系統(tǒng)的幫助，從靶點(diǎn)到候選分子包含動(dòng)物實(shí)驗(yàn)驗(yàn)證僅需46天。Insilico Medicine 早前完成了由啟明創(chuàng)投領(lǐng)投的3700萬美元的B輪融資。
Insilico Medicine, a company developing end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu ChiaTai Fenghai Pharmaceutical Co., Ltd. (CTFH), taking on previously undruggable targets. This partnership is expected to accelerate drug discovery and development with an AI-enabled platform for triple-negative breast cancer. Insilico Medicine will be eligible to receive up to $200mm for the achievement of milestone payments and royalties based on the net sales on the products from the collaboration.
CTFH is an active adopter of state-of-the-art technologies and has achieved significant milestones in first-in-class drug development. Wenyu Xia, General Manager of CTFH, said, “We are very pleased to establish the partnership with Insilico Medicine, entering the new era of AI-enabled drug development. We look forward to a long-term partnership with Insilico Medicine. As the premier AI drug discovery company in the industry, Insilico Medicine has demonstrated capabilities to generate novel molecules with specified properties using its next-generation AI platform. We believe that this collaboration will speed up the R&D process, reduce the cost and provide greater benefits to patients.”
Last month, Insilico Medicine published a landmark paper in Nature Biotechnology, demonstrating the application of its generative tensorial reinforcement learning systems in the generation of novel molecules for simple kinases in 46 days, including experimental validation. It also announced a $37 million round led by Qiming Venture Partners.
